GPI promotes immunosuppression in anaplastic thyroid carcinoma via O-GlcNAcylated THBS1-mediated myeloid cell crosstalk
Cancer Letters · 2026-09 · 656 · 218650
DOI: 10.1016/j.canlet.2026.218650 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-09. Verfasst von Tong Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou M…. Hauptthemen laut MEDLINE: Thrombospondin 1, Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms, Myeloid Cells. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Medical Science and Technology Project of Zhejiang Province, Natural Science Foundation of Zhejiang Province, Key Research and Development Program of Zhejiang Province.
Abstract (Originalsprache)
The aggressive and immunotherapy-resistant characteristics of anaplastic thyroid carcinoma (ATC) are driven by an immunosuppressive tumor microenvironment and intercellular crosstalk; however, its regulatory mechanisms remain poorly understood. Here, we identified Glucose-6-Phosphate Isomerase (GPI) as a pivotal metabolic immune checkpoint that orchestrates myeloid cells-driven immunosuppression in ATC. We demonstrated that GPI enhances the hexosamine biosynthesis pathway to promote O-GlcNAcylation of thrombospondin-1 (THBS1) at serine-1068. This site-specific modification competes with ubiquitination to stabilize THBS1 and augment its secretion. Released THBS1 engages macrophages to trigger a CEBPB-dependent transcriptional program that drives the expression of the chemokine CCL2. Macrophage-derived CCL2 then acts on tumor-associated neutrophils, promoting their STAT3-dependent differentiation into polymorphonuclear myeloid-derived suppressor cells, which ultimately suppresses CD8+ T cell function. Genetic deletion of either GPI or THBS1 robustly inhibited tumor growth and reversed immunosuppression in vivo. To intervene this axis, we repurposed the multi-kinase inhibitor Regorafenib as a novel GPI inhibitor. We confirmed that Regorafenib disrupts this entire axis and, in combination with anti-PD-1 therapy in ATC, overcomes immunosuppression to elicit potent anti-tumor immunity. Our studies revealed the GPI/O-GlcNAcylation/THBS1 signal as a master regulator of myeloid cell crosstalk and established a novel therapeutic strategy for targeting this metabolic checkpoint to potentiate ATC immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China; Zhejiang Provincial Clinica…
- Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
- Zhejiang Provincial Clinical Research Center for Malignant Tumor, Hangzhou, 310014, China; Zhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Hangzhou, 310014, China; Otolaryngology & Head and…
Förderung
- Medical Science and Technology Project of Zhejiang Province
- Natural Science Foundation of Zhejiang Province
- Key Research and Development Program of Zhejiang Province
- National Natural Science Foundation of China
Zitieren
APA
Xu, T., Lu, B., Song, F., Jiang, B., Gong, S., Ma, Y., Zhang, Y., Huang, P., & Ge, M. (2026). GPI promotes immunosuppression in anaplastic thyroid carcinoma via O-GlcNAcylated THBS1-mediated myeloid cell crosstalk. Cancer Letters, 656, 218650. https://doi.org/10.1016/j.canlet.2026.218650
Vancouver
Xu T, Lu B, Song F, Jiang B, Gong S, Ma Y, et al. GPI promotes immunosuppression in anaplastic thyroid carcinoma via O-GlcNAcylated THBS1-mediated myeloid cell crosstalk. Cancer Letters. 2026;656:218650. doi:10.1016/j.canlet.2026.218650
BibTeX
@article{Xu2026,
author = {Xu, Tong and Lu, Bin and Song, Feifeng and Jiang, Bo and Gong, Shaobo and Ma, Yuxiang and Zhang, Yiwen and Huang, Ping and Ge, Minghua},
title = {GPI promotes immunosuppression in anaplastic thyroid carcinoma via O-GlcNAcylated THBS1-mediated myeloid cell crosstalk},
journal = {Cancer Letters},
year = {2026},
volume = {656},
pages = {218650},
doi = {10.1016/j.canlet.2026.218650}
}
EUVIMED